IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to five newly hired employees on April 30, 2026 under its 2023 Inducement Plan.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to five newly hired employees on April 30, 2026 under its 2023 Inducement Plan. An aggregate of 237,800 options were granted at an exercise price of $29.10 per share, equal to the April 30 closing price.

The options have a 10-year term and vest over four years (25% after one year, then monthly over three years), subject to continued service.

Argus May 1 session

-3.13% close to close Open Argus

Details

News Market Reaction – IDYA

On May 1, the day this news came out, IDYA closed 3.13% below the previous close.

Data tracked by StockTitan Argus for the May 1 session.

Key Figures

Option grant size: 237,800 shares Employees granted: 5 employees Exercise price: $29.10 per share +4 more

Option grant size

237,800 shares

Aggregate non‑qualified stock options granted to five new employees

Employees granted

5 employees

Recipients of inducement stock option grants

Exercise price

$29.10 per share

Equal to Nasdaq closing price on April 30, 2026

Option term

10 years

Contractual term of the inducement stock options

Vesting period

4 years

Overall vesting schedule for the options

Initial vesting tranche

25%

Portion vesting on first anniversary of vesting commencement date

Remaining vesting

75% over 3 years

Balance vesting in equal monthly installments thereafter

Historical Context

5 past events · Latest: Apr 21

5 events

1. Apr 21

   Conference presentation

   24h Move

   -5.3%

   ASCO 2026 late‑breaking oral presentation of OptimUM‑02 complete data announced.

2. Apr 13

   Clinical topline data

   24h Move

   +7.6%

   Positive Phase 2/3 OptimUM‑02 topline results for darovasertib plus crizotinib reported.

3. Apr 10

   Data timing update

   24h Move

   +7.6%

   Announcement of timing for upcoming OptimUM‑02 topline data release and webcast.

4. Apr 06

   First‑patient‑in

   24h Move

   -1.2%

   First‑patient‑in for Phase 1 trial of IDE574 in multiple solid tumor indications.

5. Mar 30

   First‑patient‑in

   24h Move

   +3.3%

   First‑patient‑in for Phase 1 combination study of IDE849 and IDE161 in DLL3 tumors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 237,800 shares of the Company's common stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 30, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 237,800 shares of the Company's common stock to five newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $29.10 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302759783.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IDEAYA (IDYA) grant in the April 30, 2026 inducement awards?

IDEAYA granted an aggregate of 237,800 non-qualified stock options to five new employees. According to the company, the awards were issued under the 2023 Inducement Plan as material inducements for new hires.

What is the exercise price and term of the IDEAYA (IDYA) inducement stock options?

The inducement options carry an exercise price of $29.10 per share and a 10-year term. According to the company, the exercise price equals the closing market price on the grant date, April 30, 2026.

How do the IDEAYA (IDYA) inducement options vest for the newly hired employees?

Vesting occurs over four years: 25% vests on the first anniversary, then the remaining 75% vests monthly over three years. According to the company, vesting is conditioned on each employee's continued service on each vesting date.

Under which plan were IDEAYA (IDYA) April 30, 2026 grants made and why?

The grants were made under the 2023 Inducement Plan to induce employment of individuals not previously employees. According to the company, this usage complies with Nasdaq Listing Rule 5635(c)(4) for inducement awards.

Will the IDEAYA (IDYA) inducement awards immediately dilute existing shareholders?

The awards represent potential future dilution if options are exercised, but are not yet exercised shares. According to the company, 237,800 options were granted and will only dilute outstanding shares upon exercise, subject to vesting and exercise events.